Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
|Articles|August 1, 1996
The American Journal of Managed Care
- July/August 1996
- Volume 2
- Issue 7
CHINs: Pharmacy Can't Afford to be Left Out
Advertisement
Articles in this issue
about 30 years ago
Understanding the Behavioral Response to Medical Innovationabout 30 years ago
Improving Patient Satisfaction with Warfarin Managementabout 30 years ago
The Third Generation of Managed Careabout 30 years ago
Results of a Smoking-Cessation Program in a Managed Care Settingabout 30 years ago
Breast Cancer Screening: Who, When, and HowAdvertisement
Related to this article
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.
Hidradenitis suppurativa diagnosis often takes 7 to 10 years, and patients with skin of color often present with tunnels and scarring already in place.
In HIV, lymphoma survival tracks tumor stage and CD4 count, not viral suppression, a Spanish cohort shows.
Polyphenols show lab promise for endometriosis, but human evidence is thin, and the best resveratrol pain trial was negative.
Those using e-cigarettes were more likely to develop cataracts, and those receiving cataract surgery less likely to develop depression and anxiety.
Advertisement
Advertisement
Trending on AJMC
1
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
2
Using Complement Inhibitors in GA Comes With Pros and Cons
3
Pairing VYD2311 With mRNA COVID-19 Vaccines: Michael Mina, MD, PhD
4
New Mechanism of DME Treatment Highlights Clinical Trial Updates
5